Literature DB >> 7332731

Lignocaine disposition in blood in epilepsy.

P A Routledge, W W Stargel, A L Finn, A Barchowsky, D G Shand.   

Abstract

1 The plasma concentration of alpha 1-acid glycoprotein (AAG) was significantly greater in 27 epileptic subjects receiving anticonvulsants compared with 27 age- and sex-matched drug-free control subjects. 2 Increased AAG concentration was associated with enhanced lignocaine binding in the plasma of epileptics. 3 Increased AAG concentration was also associated with a redistribution of lignocaine out of red cells and into plasma thus lowering the blood to plasma concentration ratio. 4 Enhanced lignocaine binding in epileptics receiving anticonvulsant therapy may result in lower free (unbound) plasma concentrations of the drug compared to normal subjects with equivalent total plasma lignocaine concentrations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332731      PMCID: PMC1401970          DOI: 10.1111/j.1365-2125.1981.tb01286.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

2.  Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties, and anesthetic activity.

Authors:  G T Tucker; R N Boyes; P O Bridenbaugh; D C Moore
Journal:  Anesthesiology       Date:  1970-09       Impact factor: 7.892

3.  Induction of sex hormone binding globulin by phenytoin.

Authors:  A Victor; P O Lundberg; E D Johansson
Journal:  Br Med J       Date:  1977-10-08

4.  Lidocaine plasma protein binding.

Authors:  P A Routledge; A Barchowsky; T D Bjornsson; B B Kitchell; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

5.  Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction.

Authors:  P A Routledge; W W Stargel; G S Wagner; D G Shand
Journal:  Ann Intern Med       Date:  1980-11       Impact factor: 25.391

6.  Sex-related differences in the plasma protein binding of lignocaine and diazepam.

Authors:  P A Routledge; W W Stargel; B B Kitchell; A Barchowsky; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

7.  The effect of oral contraceptive steroids and enzyme inducing drugs on sex hormone binding globulin capacity in women [proceedings].

Authors:  D J Back; A M Breckenridge; F E Crawford; M MacIver; M L Orme; E Perucca; A Richens; P H Rowe; E Smith
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

8.  Binding of quinidine in sera with different levels of triglycerides, cholesterol, and orosomucoid protein.

Authors:  O G Nilsen; P Leren; I Aakesson; S Jacobsen
Journal:  Biochem Pharmacol       Date:  1978-03-15       Impact factor: 5.858

9.  Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients.

Authors:  E Perucca; A Richens
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

  9 in total
  20 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

3.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

4.  Drug binding in the undernourished: a study of the binding of propranolol to alpha 1-acid glycoprotein.

Authors:  V Jagadeesan; K Krishnaswamy
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Enzyme induction with rifampicin; lipoproteins and drug binding to alpha 1-acid glycoprotein.

Authors:  J Feely; M Clee; L Pereira; E Guy
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

Review 6.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  alpha 1-Acid glycoprotein and plasma lidocaine binding.

Authors:  D G Shand
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 8.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

9.  Serum alpha 1-acid glycoprotein and the binding of drugs in obesity.

Authors:  I H Benedek; W D Fiske; W O Griffen; R M Bell; R A Blouin; P J McNamara
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

10.  Induction of propranolol metabolism by rifampicin.

Authors:  R J Herman; K Nakamura; G R Wilkinson; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.